Navigation Links
Dyadic And CIMV Enter Into Collaboration To Commercialize Second Generation Biofuel Technology
Date:8/5/2014

ntegrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 expression system can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce. Please visit Dyadic's website at www.dyadic.com. Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic on the OTC marketplace website at www.otcmarkets.com/stock/DYAI/quote.

About CIMV
The company CIMV (Compagnie Industrielle de la Matiere Vegetale), founded in 1998, has developed a revolutionary concept of lignocellulosic biorefinery. Based on a petroleum refinery model, this allows the separation, without degradation and without environmental impact, of the three components of plant material into three intermediary products designed for industry: Biolignin™, cellulose/glucose and sugar syrups in C5. These products can be substituted for commodities of a fossil origin used in the composition of everyday consumer products (glue, insulation, fuel, plastics, etc.).

The extraction of a pure lignin is the unique scientific breakthrough of CIMV's process and the basis of its profitability, since lignin is the equivalent of a petroleum phenol in main applications. The feedstock used in the CIMV process is non-food material and comes from agricultural byproducts (cereal straw, bagasse from sugarcane and sweet sorghum) or fiber cr
'/>"/>

SOURCE Dyadic International, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Thomas Dubinski joins Dyadic as Chief Financial Officer
2. Dyadic International To Present At Two Major Conferences In December 2013
3. Dyadic International Reports Third Quarter 2013 Financial Results
4. Dyadic International To Announce Third Quarter 2013 Financial Results And Host Conference Call On Thursday, November 14, 2013
5. Dyadic International Reports Second Quarter 2013 Financial Results
6. Dyadic International To Present At World Biotechnology Congress 2013 And BIO World Congress On Industrial Biotech
7. Dyadic International Reports First Quarter 2013 Financial Results
8. Dyadic International To Announce First Quarter 2013 Financial Results And Host Conference Call On Wednesday, May 15, 2013
9. Danai Brooks Joins Dyadic International as Chief Operating Officer
10. Dyadic International To Speak At Advanced Biofuels Leadership Conference Panel Discussion
11. Dyadic International To Present At World Biofuels Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... April 21, 2015 AbilTo, Inc., the nation,s ... abstract submission has been accepted as a presentation to ... meeting taking place on June 5-6, 2015 in ... the American Diabetes Association, the cost of diabetes to ... As a result of increased inpatient, outpatient, and pharmacy ...
(Date:4/21/2015)... 21, 2015 Immune Pharmaceuticals Inc., or "Immune" ... Directors has elected Rene-Pierre Azria as a ... Committee, with oversight on strategic and financial transactions. Mr. ... Committee, the Compensation Committee and the Corporate Governance and ... commented: "I have a long-time interest in Life Sciences ...
(Date:4/21/2015)... April 21, 2015  Novogen Limited (ASX:NRT; NASDAQ: ... advises that it has entered into definitive agreements ... shares plus one attaching 6-month option and half ... share issued, to institutional investors in ... placement for aggregate gross proceeds of approximately AU$15,500,000 ...
(Date:4/21/2015)... 21, 2015 Leading-edge research ... applications will be presented at the 2nd ... regulators and clinicians from academia, industry and ... by Invibio Biomaterial Solutions. The world-leading solutions ... in manufacturing and R&D for medical-device manufacturers, ...
Breaking Biology Technology:AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 2AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 3Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 2Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 3Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 4Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 2Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 3Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 4Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 5Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 62nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 22nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 3
... New York on Monday, September 10th, SAN ... biopharmaceutical company developing patient-specific, active,immunotherapies for the treatment ... President and Chief Executive Officer, will present at,the ... p.m. Eastern,time on Monday, September 10, 2007. The ...
... CDC to Ensure US,s Preparedness ... Emergency, CAMBRIDGE, England and CAMBRIDGE, Massachusetts, September ... company, announced today that the US Food and ... Vaccine, Live) vaccine,for protection against smallpox. The vaccine ...
... announced,today that one year findings from the ... net clinical benefit for patients with acute,ST-segment ... Heparin (UFH). The ExTRACT-TIMI 25 and ... sessions at the European Society of Cardiology ...
Cached Biology Technology:FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox 2FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox 3FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox 4FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox 5New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 2New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 3New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 4New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 5
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
(Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
(Date:4/1/2015)... 1, 2015   Medisafe ™, the leading global ... iOS and Android smartphones and ... into the platform to allow patients to track and ... first time, patients will be able to visualize in ... important biometrics, such as glucose levels and blood pressure. ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... weapon in the arsenal against cancer: Nanoparticles that identify, ... cells alone. Led by Carl Batt, the Liberty ... nanoparticles shaped something like a dumbbell made ... They then attached antibodies, which target a molecule found ...
... of God and the nature of religion, two distinguished ... in evolutionary biology with a focus on brain science, ... Tiger and pioneering neuroscientist Michael McGuire elucidate perennial questions ... arise? What is its source? And why does every ...
... breakthrough treatments for the most common cancers could soon come ... At the ESMO Conference on Sarcoma and GIST, to ... 2010, researchers and some of the world,s leading experts will ... found in muscle, blood vessels, deep skin tissues, nerves and ...
Cached Biology News:Like little golden assassins, 'smart' nanoparticles identify, target and kill cancer cells 2Which came first: Religion or the brain? 2Spotlight on rare tumors in hunt for new cancer treatments 2
EoProbe Eosinophil Staining Kit, 1 Kit...
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
...
LabFax: Immunochemistry...
Biology Products: